Scott E. Schaus, PhD
Professor, Chemistry
Biography
Professor Schaus received his Ph.D. in Organic Chemistry with Eric N. Jacobsen at Harvard University in 1999 and did postdoctoral studies in Andy Myers’ laboratory at Harvard University as an NIH fellow.
Research in the Schaus Group is focused in two major areas: enantioselective catalytic synthetic methodologies for chemical synthesis and biomedical research, the latter conducted at the Boston University Center for Molecular Discovery. Catalytic methods developed in the Schaus Research Laboratories include asymmetric Mannich reactions, enantioselective boronate reactions, and metal-promoted condensation reactions.
Asymmetric Mannich Reactions – The use of cinchona amine, acid, and diol catalysis in the synthesis of chiral amines and heterocycles.
Enantioselective Boronate Catalysis – The development of methodologies to construct chiral building blocks and natural products using boronates.
Biomedical Research – In conjunction with the CMD-BU, advance translational science in the treatment of cancer and infectious disease.
Hepatocellular Carcinoma – Taking on liver cancer in the lab.
Neglected Tropical Disease – BU Researchers Work against Deadly, Disfiguring Disease. Pharmaceutical giant GSK chooses team in its new competition.
Techniques & Resources:
Organic Synthesis techniques are used and include modern methods for synthesis, purification, and analysis of organic molecules.
The Center for Molecular Discovery (CMD-BU) is an NIH-funded Center at Boston University which focuses on development of new methodologies for the synthesis of chemical libraries and biomedical research.
Other Positions
- Assistant Professor, Pharmacology, Physiology & Biophysics, Boston University Chobanian & Avedisian School of Medicine
- Member, BU-BMC Cancer Center, Boston University
- Member, Evans Center for Interdisciplinary Biomedical Research, Boston University
Education
- Harvard University, PhD
- Boston University, DEng
- Boston University, BA
Publications
- Published on 1/23/2023
Kavouris JA, McCall LI, Giardini MA, De Muylder G, Thomas D, Garcia-Pérez A, Cantizani J, Cotillo I, Fiandor JM, McKerrow JH, De Oliveira CI, Siqueira-Neto JL, González S, Brown LE, Schaus SE. Discovery of pyrazolopyrrolidinones as potent, broad-spectrum inhibitors of Leishmania infection. Front Trop Dis. 2023; 3. PMID: 36818551.
Read at: PubMed - Published on 10/12/2022
Brown LE, Seitz S, Kondas AV, Marcyk PT, Filone CM, Hossain MM, Schaus SE, Olson VA, Connor JH. Identification of Small Molecules with Improved Potency against Orthopoxviruses from Vaccinia to Smallpox. Antimicrob Agents Chemother. 2022 Nov 15; 66(11):e0084122. PMID: 36222522.
Read at: PubMed - Published on 6/15/2022
Yunes SA, Willoughby JLS, Kwan JH, Biagi JM, Pokharel N, Chin HG, York EA, Su KC, George K, Shah JV, Emili A, Schaus SE, Hansen U. Factor quinolinone inhibitors disrupt spindles and multiple LSF (TFCP2)-protein interactions in mitosis, including with microtubule-associated proteins. PLoS One. 2022; 17(6):e0268857. PMID: 35704642.
Read at: PubMed - Published on 6/13/2022
Lotfollahzadeh S, Lo D, York EA, Napoleon MA, Yin W, Elzinad N, Le J, Zhang M, Yang X, Morrissey A, Elsadawi M, Zhao Q, Schaus SE, Hansen U, Chitalia VC. Pharmacologic Manipulation of Late SV40 Factor Suppresses Wnt Signaling and Inhibits Growth of Allogeneic and Syngeneic Colon Cancer Xenografts. Am J Pathol. 2022 Aug; 192(8):1167-1185. PMID: 35710032.
Read at: PubMed - Published on 12/7/2021
Stoiber P, Scribani Rossi P, Pokharel N, Germany JL, York EA, Schaus SE, Hansen U. Factor quinolinone inhibitors alter cell morphology and motility by destabilizing interphase microtubules. Sci Rep. 2021 12 07; 11(1):23564. PMID: 34876605.
Read at: PubMed - Published on 6/15/2020
Willoughby JLS, George K, Roberto MP, Chin HG, Stoiber P, Shin H, Pedamallu CS, Schaus SE, Fitzgerald K, Shah J, Hansen U. Targeting the oncogene LSF with either the small molecule inhibitor FQI1 or siRNA causes mitotic delays with unaligned chromosomes, resulting in cell death or senescence. BMC Cancer. 2020 Jun 15; 20(1):552. PMID: 32539694.
Read at: PubMed - Published on 3/6/2020
Stoiber P, Ekladious I, Zhao Q, Colson YL, Schaus SE, Hansen U, Grinstaff MW. Expansile Nanoparticles Encapsulate Factor Quinolinone Inhibitor 1 and Accumulate in Murine Liver upon Intravenous Administration. Biomacromolecules. 2020 04 13; 21(4):1499-1506. PMID: 32101401.
Read at: PubMed - Published on 2/28/2020
Chin HG, Esteve PO, Ruse C, Lee J, Schaus SE, Pradhan S, Hansen U. The microtubule-associated histone methyltransferase SET8, facilitated by transcription factor LSF, methylates a-tubulin. J Biol Chem. 2020 04 03; 295(14):4748-4759. PMID: 32111740.
Read at: PubMed - Published on 12/26/2018
Smith MJ, Reichl KD, Escobar RA, Heavey TJ, Coker DF, Schaus SE, Porco JA. Asymmetric Synthesis of Griffipavixanthone Employing a Chiral Phosphoric Acid-Catalyzed Cycloaddition. J Am Chem Soc. 2019 01 09; 141(1):148-153. PMID: 30566336.
Read at: PubMed - Published on 12/17/2018
Wong CR, Hummel G, Cai Y, Schaus SE, Panek JS. [4 + 2]-Cycloaddition and 1,4-Addition of ortho-Quinone Methides by a Chiral Crotyl Silane. Org Lett. 2019 01 04; 21(1):32-35. PMID: 30557029.
Read at: PubMed
View 64 more publications: View full profile at BUMC